• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The WOEST trial: Double vs. triple therapy in patients requiring PCI and anticoagulation [Classics Series]

byAndrew Cheung, MD MBA
October 5, 2015
in General Medicine Classics, Surgery Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients requiring percutaneous coronary intervention (PCI) and long-term oral anticoagulation, treating with clopidogrel alone (i.e., double therapy) significantly reduced the risk of bleeding when compared to a combination of aspirin and clopidogrel (i.e., triple therapy).

2. There were no differences between the two groups in the risk of myocardial infarction, stroke, target vessel revascularization, or stent thrombosis.

Original Date of Publication: March 2013

Study Rundown: Many patients, like those with atrial fibrillation or mechanical heart valves, require long-term oral anticoagulation. A significant proportion of these patients also suffer from ischemic coronary artery disease requiring PCI, and subsequently, require dual antiplatelet therapy for a certain period of time in addition to anticoagulation. Combining these therapies, however, results in a high-risk of bleeding to the patient, with an uncertain benefit in reducing the risk of thrombosis. The purpose of the What is the Optimal antiplatelet and anticoagulation therapy in patients with oral anticoagulation and coronary StenTing (WOEST) trial sought to address these uncertainties. Patients who had an indication for long-term anticoagulation and required PCI were recruited to the trial and randomized to either antiplatelet therapy with clopidogrel alone (i.e., double therapy), or a combination of aspirin and clopidogrel (i.e., triple therapy), which was standard at the time, in addition to their anticoagulation. In summary, patients treated with double therapy had a significantly lower risk of bleeding than those on triple therapy. Moreover, there were no significant differences between the two groups in the risk of myocardial infarction, stroke, target vessel revascularization or stent thrombosis.

Click to read the study in The Lancet

In-Depth [randomized controlled trial]: This open-label, randomized trial was conducted at 15 sites in the Netherlands and Belgium. Patients were eligible for the study if they were between 18 and 80 years of age, had an indication for long-term anticoagulation (e.g., atrial fibrillation, mechanical heart valve), and had a severe coronary lesion with indication for PCI. Exclusion criteria included a history of intracranial bleeding, cardiogenic shock, a contraindication to aspirin, clopidogrel or both, thrombocytopenia with platelet count <50×109/L, major bleeding in the past 12 months, and pregnancy. Included patients were randomized to either clopidogrel alone (i.e., double therapy) or a combination of aspirin and clopidogrel (i.e., triple therapy) in addition to their anticoagulation. In the case of bare metal stents, antiplatelets were taken for 1 month and up to 1 year, while antiplatelets were administered for at least 1 year in patients with drug-eluting stents. The primary endpoint was any bleeding episode during the 1-year follow-up. The composite secondary endpoint included death, myocardial infarction, stroke, target-vessel revascularization and stent thrombosis.

A total of 573 patients underwent randomization. At 1-year, patients in the double therapy group experienced significantly lower risk of overall bleeding compared to the triple therapy group (HR 0.40, 95%CI 0.28-0.58, p < 0.0001). The rates of major bleeding, however, were no different between the two groups (HR 0.56, 95%CI 0.25-1.27, p = 0.159). Patients in the double therapy group also experienced significantly lower risk of the composite secondary endpoint (HR 0.60, 95%CI 0.38-0.94, p = 0.025), as they had significantly lower risk of death (HR 0.39, 95%CI 0.16-0.93, p = 0.027) than patients on triple therapy. There were no significant differences between the two groups in the risk of myocardial infarction, stroke, target vessel revascularization or stent thrombosis.

RELATED REPORTS

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]

RE-VERSE AD Trial: Idarucizumab for the Reversal of Anticoagulation by Dabigatran [Classics Series]

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anticoagulationantiplateletwoest trial
Previous Post

Intrapartum antibiotics associated with altered infant gut microbiome

Next Post

Adolescent views on marijuana and alcohol associated with future DUI

RelatedReports

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk
StudyGraphics

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

June 28, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Critical, Emergent and Pulmonary Care Classics

ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]

June 21, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Critical, Emergent and Pulmonary Care Classics

RE-VERSE AD Trial: Idarucizumab for the Reversal of Anticoagulation by Dabigatran [Classics Series]

June 20, 2022
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Increased risk of intracranial hemorrhage with aspirin and unfractionated heparin use for endovascular stroke treatment

March 22, 2022
Next Post
Adolescent views on marijuana and alcohol associated with future DUI

Adolescent views on marijuana and alcohol associated with future DUI

Beta-blockers associated with worse outcomes in non-cardiac perioperative settings

Beta-blockers associated with worse outcomes in non-cardiac perioperative settings

Government-funded initiatives provide important supports to low-income HIV patients

Increased incidence of certain cancers in HIV-positive individuals

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.